‘Disappointed’ UCB And Amgen Will Appeal CHMP’s Negative Evenity Decision

The EMA’s CHMP cited concerns over cardiovascular side effects as the reason why it took a negative stance on Evenity’s use in the EU for treating severe osteoporosis.